ACADIA Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 8, 2018
July 30 2018 - 9:00AM
Business Wire
ACADIA to Host Conference Call and Webcast on
Wednesday, August 8, 2018, at 5:00 p.m. Eastern Time
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines that address unmet medical needs in central
nervous system disorders, today announced that it will report its
financial results for the second quarter ended June 30, 2018 on
Wednesday, August 8, 2018, after the U.S. financial markets close.
ACADIA’s management will host a conference call and webcast on
Wednesday, August 8, 2018, at 5:00 p.m. Eastern Time to discuss
ACADIA’s financial results and operations.
The conference call may be accessed by dialing 844-821-1109 for
participants in the United States or Canada and 830-865-2550 for
international callers (reference passcode 7987107). A telephone
replay of the conference call may be accessed through August 22,
2018 by dialing 855-859-2056 for callers in the United States or
Canada and 404-537-3406 for international callers (reference
passcode 7987107). The conference call also will be webcast live on
ACADIA’s website, www.acadia-pharm.com under the investors section
and will be archived there until August 22, 2018.
About ACADIA PharmaceuticalsACADIA is a biopharmaceutical
company focused on the development and commercialization of
innovative medicines to address unmet medical needs in central
nervous system disorders. ACADIA has developed and is
commercializing the first and only medicine approved for the
treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis. In addition, ACADIA has ongoing
clinical development efforts in additional areas with significant
unmet need including dementia-related psychosis, schizophrenia
inadequate response, schizophrenia-negative symptoms and major
depressive disorder. This press release and further information
about ACADIA can be found at: www.acadia-pharm.com.
Forward-Looking StatementsStatements in this press release that
are not strictly historical in nature are forward-looking
statements. These statements include but are not limited to
statements regarding the timing of future events. These statements
are only predictions based on current information and expectations
and involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development, approval and
commercialization. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year
ended December 31, 2017 as well as ACADIA’s subsequent filings with
the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. All forward-looking statements are qualified in their
entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180730005094/en/
Investor Contact:ACADIA Pharmaceuticals Inc.Elena Ridloff,
CFA(858) 558-2871ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024